Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer-Reference-Cited by-同舟云学术

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

Published:1999-11-26 Issue:8 Volume:81 Page:1419-1425
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Tokuda Y,Watanabe T,Omuro Y,Ando M,Katsumata N,Okumura A,Ohta M,Fujii H,Sasaki Y,Niwa T,Tajima T

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6690343.pdf

Reference24 articles.

1. Baselga, J, Tripathy, D, Mendelsohn, J, Baughman, S, Benz, CC, Danits, L, Sklarin, NT, Seidman, AD, Hudis, CA, Moore, J, Rosen, PP, Twaddell, T, Henderson, IC & Norton, L (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744.

2. Carter, P, Presta, L, Gorman, CM, Ridgway, JBB, Henner, D, Wong, WLT, Rowland, AM, Kotts, C, Carver, ME & Shepard, HM (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289.

3. Coussens, L, Yang-Feng, TL, Liao, Y-C, Chen, E, Gray, A, McGrath, J, Seeburg, PH, Liebermann, TW, Schlessinger, J, Franke, U, Levison, A & Ullrich, A (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139.

4. De Potter, CR, Van Daele, S, Van De Vijver, MJ, Pauwels, C, Maertens, G, De Boever, J, Vandekerckhove, D & Roels, H (1989). The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology 15: 315–326.

5. Drebin, JA, Link, VC, Stern, DF, Weinberg, RA & Green, MI (1985). Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 695–706.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients;Cancer Chemotherapy and Pharmacology;2024-08-23

2. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies;mAbs;2024-03-04

3. Mechanistic Modeling of Intrathecal Chemotherapy Pharmacokinetics in the Human Central Nervous System;Clinical Cancer Research;2024-01-30

4. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies;British Journal of Clinical Pharmacology;2023-05

5. The Challenges of Treating Patients with Breast Cancer and Obesity;Cancers;2023-04-28